decisionhealth Newsletters, Part B News - 2021 Issue 3 (March)
FDA issues emergency authorization for new COVID-19 antibody treatment
Subscribe or sign in to view the full article.
Article Overview
This article explains an FDA emergency use authorization related to a COVID-19 antibody combination treatment and summarizes the Medicare billing and payment context that followed. It is written for providers, coders, and billing staff who need to track how new COVID-19 therapeutics are handled operationally, including the relevant HCPCS Level II reporting codes and general reimbursement considerations. The article also outlines the high-level authorization limitations and references CMS payment policy considerations for drug and administration services.
Why This Topic Matters
Newly authorized COVID-19 therapies can affect medication access, claim reporting, and Medicare reimbursement. Understanding the scope of the authorization and the related HCPCS Level II codes helps providers and billing teams prepare for compliant reporting and payment processing.
What You Will Learn
- What the FDA emergency use authorization covers at a high level
- How CMS discussed billing and payment implications for the therapy
- Which HCPCS Level II reporting codes are associated with the product and administration
- What general limitations were noted for use of the treatment
- How federal agencies framed provider access, reimbursement, and administration considerations
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle teams
- Hospital outpatient departments
- Physician practices
- Healthcare compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com